Staar Surgical kommt ganz still und heimlich! Wer ist dabei?

Bevorstehender Unternehmenstermin

Bei Staar Surgical steht morgen der Termin "Quartalsmitteilung" an. Es wird ein EPS von -0,58$ geschätzt.
39 Nutzer haben Staar Surgical im Portfolio und 53 unserer Nutzer haben Staar Surgical auf der Watchlist.

Weitere Nachrichten zu Staar Surgical finden Sie auf der Staar Surgical Wertpapierdetailseite im Bereich "Neuigkeiten" und unter "Übersicht".
Eine Übersicht aller Unternehmenstermine finden Sie hier.

Staar Surgical Insidertrade Update

Am 07.04.2025 hat Broadwood Partners, L.P. 138.054 Aktien, zu einem Kurs von 15,61 USD gekauft.

Wie ist Ihre Meinung dazu? Diskutieren Sie mit!
Quelle: Staar Surgical Insidertrades

Staar Surgical Insidertrade Update

Am 03.03.2025 hat Broadwood Partners, L.P. 249.503 Aktien, zu einem Kurs von 16,64 USD gekauft.

Wie ist Ihre Meinung dazu? Diskutieren Sie mit!
Quelle: Staar Surgical Insidertrades

Veröffentlichung von Unternehmenszahlen

Bei Staar Surgical steht morgen der Termin "Quartalsmitteilung" vor Öffnung an.
39 Nutzer haben Staar Surgical im Portfolio und 54 unserer Nutzer haben Staar Surgical auf der Watchlist.
Wie ist Ihre Meinung zu den Ergebnissen? Diskutieren Sie mit!

Veröffentlichung von Unternehmenszahlen

Bei Staar Surgical steht morgen der Termin "Quartalsmitteilung" an. Es wird ein EPS von -0,03$ geschätzt.
39 Nutzer haben Staar Surgical im Portfolio und 54 unserer Nutzer haben Staar Surgical auf der Watchlist.
Wie ist Ihre Meinung zu den Ergebnissen? Diskutieren Sie mit!

Mensch das waren noch Zeiten damals...aber ich glaube jetzt könnte die Zeit von STAAR Surgical endlich gekommen sein! Also ich bin bereits eingestiegen, der Allzeit-Chart sieht für mich ziemlich vielversprechend aus bei den guten Aussichten. Ich will natürlich nicht pushen aber vielleicht ist ja noch jemand drin und wir können hier etwas über die Aktie und deren Aussichten plaudern?

Aktuell steht STAA bei $5,24



PS: Danke fürs Freischalten SkyMod!

hallo, habe auch staa im depot
welchen kurzziel hält ihr für real ??
ich denke die 20 $ müsste doch machbar sein oder ?

Guten Tag,

bin bei Staar bei 2,65 eingestiegen und bin derzeit wirklich zufrieden damit. Ich werde sie auch im Moment nicht mehr hergeben.
Weiß den schon jemand wie demnächst die Zahlen ausfallen werden???

Hallo,

hat denn niemand hier in Deutschland "Staar" in seinem Depot?

Predo

Dow Jones Business News
Staar Surgical`s Shares up After Positive Study on Lenses
Thursday May 15, 1:51 pm ET
By Tiffany Kary


NEW YORK -- A study in ophthalmology journal Cornea had investors seeing clear benefits for Staar Surgical Co. (NasdaqNM:STAA - News) and its implantable contact lenses Thursday.
ADVERTISEMENT


In afternoon trading on the Nasdaq National Market, shares of Staar Surgical rose $1.68, or 17%, to $11.83, as the maker of minimally invasive ophthalmic products touted the journal`s report that its implantable contact lenses, or ICL, are safer and more effective than Lasik eye surgery for correcting myopia, or nearsightedness.

The Monrovia, Calif.-based company, which also makes glaucoma treatments and lenses for cataracts, recently submitted an application to the Food and Drug Administration (News - Websites) for U.S. approval of the lenses, which are inserted into the eye through a small incision. Staar already sells the lenses in international markets, according to a company spokesman.

The spokesman also said international markets make up 54% of the company`s revenue overall, but a small percent of that revenue comes from the lenses.

Adams, Harkness & Hill analyst Ryan Rauch said the study was good news for Staar, as it indicated that the company may now be able to take some of Lasik`s business in the market for mild to medium myopia. Expectations that the company would dominate in the market for severe myopia were already built into the share price, he said.

According to the study, in Cornea`s May issue, the lenses outperformed the Lasik procedure on all measures, and showed that, after six months, 7% of patients with the implanted lenses had gained two or more lines on the standard eye chart, while only 3% of Lasik patients had gained two or more lines.

The study in Cornea was done by two doctors, both of whom are consultants to Staar Surgical, according to Cornea`s Web site.

Mr. Rauch estimates that about 4.5 million people in the U.S. have mild to medium-grade myopia, and 3 million have severe myopia. With the lenses costing $ 500 to $700 each, "it`s a multibillion opportunity," Mr. Rauch said. He added that gross margins for Staar will be around 80%, and that the company is well ahead of its only competitors -- CibaVision, a unit of Novartis AG`s (NVS), and Advanced Medical Optics Inc. (NYSE:AVO - News) -- on the FDA approval front.

"We expect late 2003, early 2004 approval (for Staar)," Mr. Rauch said.

Other possible strengths for the implantable lenses could be that many people with thin corneas are advised against getting Lasik surgery, and could be an untapped market, he added.

Mr. Rauch doesn`t own shares in Staar, and Adams Harkness may seek investment- banking business with the company within 12 months.

He added that the good news for Staar won`t necessarily hurt competitors, though, because it`s "too early."

Lasik surgery, which uses a laser to treat myopia, is patented by Visx Inc. (NYSE:EYE - News) , which licenses its patents to several other companies. Bausch & Lomb Inc.`s (BOL) makes some instruments for the surgery, and LCA-Vision Inc. (NasdaqNM:LCAV - News) operates vision correction centers where the surgery is done.

-Tiffany Kary, Dow Jones Newswires; 201-938-5285; [e-mail]

Study Concludes STAAR`s ICL(TM) Is Safer and More Effective Than LASIK
Thursday May 15, 9:20 am ET
Results of Study Published in Cornea


MONROVIA, Calif., May 15 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA - News) a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that the May 2003 edition of Cornea, The Journal of Cornea and External Disease has published the findings of a study comparing the results of laser assisted in situ keratomileusis (LASIK) and implantable contact lenses (ICL).
The article entitled "Comparison of Implantable Contact Lens and Laser Assisted In Situ Keratomileusis for Moderate to High Myopia" authored by Donald R. Sanders, M.D., Ph.D. and John A. Vukich, M.D., concludes that the ICL is safer, more effective and appears to be a viable alternative to LASIK, which utilizes corneal refractive excimer lasers, in the treatment of moderate to high myopia.

In the article, the postoperative results of 210 eyes implanted with the ICL are compared with the postoperative results of 559 eyes on which LASIK surgery was performed. All of the patients were examined at one day, one week, one month, six months and one year postoperatively. The average level of myopia for the ICL patients was minus 9.1 diopters and the LASIK surgery patients had a slightly lower level of myopia at an average of minus 9.8 diopters.

Drs. Sanders and Vukich reported that in every index of BSCVA (Best Spectacle Corrected Visual Acuity), UCVA (Uncorrected Visual Acuity), predictability of refraction and stability of refraction, the ICL outperformed the LASIK procedure. After six months, the study indicated that while seven percent of ICL patients had gained two or more lines on the standard eye chart of BSCVA, only three percent of LASIK surgery patients had gained two or more lines and two percent of LASIK patients had actually lost two or more lines on the chart.

After six months, the predictability of the ICL procedure was much higher with 90% of patients within 1 diopter of attempted correction and 65% within 0.5 diopters. LASIK surgery had statistically significantly less favorable results with only 76% of patients within 1 diopter of attempted correction and 53% within 0.5 diopters after six months. The ICL also scored higher in the UCVA 20/20 or better comparison with 50% of those treated achieving 20/20 vision or better, while 35% of LASIK patients reached this level of visual acuity.

"We are very pleased with the results of this study which are quite encouraging," said David Bailey, president and CEO of STAAR Surgical. "The favorable comparisons between our industry-leading phakic technology and LASIK technology further underscore the radical paradigm shift in refractive surgery that we believe the ICL represents. This study clearly illustrates that the ICL offers patients a more predictable alternative to LASIK."

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR`s products are used by ophthalmic surgeons and include the revolutionary Implantable Contact Lens as well as innovative products designed to improve patient outcomes for cataracts and glaucoma.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products and government approval of new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the need to obtain regulatory approval for new products, acceptance of new products by medical practitioners and consumers, the rapid pace of technological change in the ophthalmic industry, general domestic and international economic conditions, and other factors beyond the control of STAAR Surgical Company, including those detailed from time to time in STAAR Surgical Company`s reports filed with the Securities and Exchange Commission. STAAR Surgical Company assumes no obligation and does not intend to update these forward-looking statements.

CONTACT: investors, Douglas Sherk, [phone], or Jennifer Cohn, [phone], or media, Sheryl Seapy, 415-272-3323, all of EVC Group, for STAAR Surgical Company




--------------------------------------------------------------------------------
Source: STAAR Surgical Company

So, wenn jetzt noch die Zahlen stimmen, dann geht es sehr schnell wieder gen Norden!
Mißmanagment, welches im Jahr 2000 ausgebügelt wurde, jetzt ein Topmann an der Spitze... die Zahlen können nun nur stetig besser werden!!!!
Deshalb:
Strong Buy!!!

winetrader


Monday July 16, 7:30 am Eastern Time
Press Release
SOURCE: STAAR Surgical Company
STAAR Surgical Receives FDA Approval for AquaFlow(TM)
Shipments to begin immediately
MONROVIA, Calif., July 16 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA - news) announced today that it has received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA) for its AquaFlow(TM) Collagen Glaucoma Drainage Device for use in the correction of open-angle Glaucoma. The Company is prepared to begin shipment of the device immediately. The AquaFlow has been approved and marketed in other countries for several years. In 1997, AquaFlow received CE Mark allowing it to be marketed throughout the European Union. Earlier this year a Medical Device Licensure was received from Health Canada, allowing the marketing of AquaFlow throughout Canada.

According to David Bailey, president and chairman of STAAR Surgical Company, ``We have made a significant investment to prepare for marketing of the AquaFlow upon FDA approval. We have trained over 300 physicians who are now ready to use the AquaFlow and shipments will begin immediately. FDA approval of the AquaFlow is a major milestone for STAAR Surgical as it opens a potential market in the U.S. of approximately $70 million.``

Stephen Bylsma, M.D. of the Shepard Eye Center in Santa Maria, California who is the medical monitor for the AquaFlow said, ``While the traditional trabeculectomy (glaucoma surgery) is very effective, the potential risks are not trivial. With the AquaFlow procedure, we have an effective way to lower intraocular pressure with much lower risks than standard trabeculectomy. This means a quicker return to normal activities for the patient and fewer visits and post-operative procedures for both patient and doctor.``

Bylsma added, ``I have been impressed by the consistent results of the AquaFlow procedure, with patients returning to normal activities much faster than with traditional glaucoma surgery. Most patients have a good lowering of intraocular pressure and remain without the need for eye drops to control their pressure.``

STAAR`s AquaFlow Collagen Glaucoma Drainage Device is implanted as part of a lower risk, non-penetrating surgical procedure for the treatment of glaucoma that helps to significantly reduce pressure in the eye. AquaFlow study patients had very few of the complications often associated with traditional glaucoma surgery. In most cases the AquaFlow surgery eliminates the need for glaucoma medications. Glaucoma is often associated with increased intraocular pressure. Left untreated, this increased pressure can damage the optic nerve resulting in a gradual decline in vision, blind spots and eventual blindness. Affecting roughly 67 million people worldwide, glaucoma is a leading cause of blindness if left untreated. In the U.S., there are an estimated 4 million people afflicted with approximately 100,000 new cases diagnosed each year. The worldwide glaucoma drug market is about $1.4 billion.

Founded in 1982, STAAR Surgical Company develops, manufactures and globally distributes medical devices for use in refractive, cataract and glaucoma surgery. The Company`s five product lines include silicone and Collamer(TM) foldable intraocular lenses and the Sonic WAVE(TM) phacoemulsification system, all of which are used during cataract surgery, the ICL(TM) (implantable contact lens) which is a refractive lens for the treatment of near- and far-sightedness and the AquaFlow(TM) Collagen Glaucoma Drainage Device. Regulatory approvals vary from market to market with all products except the Toric ICL(TM) and the 3-piece Collamer(TM) IOL available in Europe and all except the ICL(TM) in the United States

Niemand mehr investiert?????

Schon wieder 10% nach oben und das bei diesem schwachen Umfe3ld!!

MfG Pieselwitz!!

Bin heute eingestiegen!!!

MfG Pieselwitz!!

Nachdem was der neue Vorsitzende veröffentlicht, war das Management im letzten Jahr fast komplett ausgewechselt wordem. Ein Jahr der Umstrukturierung, die aber, aufgrund der schlechten Verkaufszahlen, gerechtfertigt war. Ja, man muß wohl von Mißmanagement sprechen. Dies wurde bisher nicht im medical erwähnt. die aktuellen Tätigkeiten des neuen Chefs, scheint die Saat für eine deutlich bessere Entwicklung zu sein. Seine Branchenkompetenz scheint im letzten Moment gekommen zu sein.
Der aktuelle stark gebeutelte Kurs sollte man zum Einstieg oder zum Nachkauf nutzen. Im Laufe des Jahres sollte man erkennen können, daß es im Verkauf wieder gegen Norden geht.(trotz starken Dollar und inländischer Konjunkturabschwächung)
Im amerikanischen board wurde der Führungswechsel ebenfalls befürwortet.

winetrader

Tuesday March 20, 5:03 pm Eastern Time
STAAR Surgical has Q4 loss, sees fiscal 2001 break-even
MONROVIA, Calif., March 20 (Reuters) - STAAR Surgical Co. (NasdaqNM:STAA - news), a maker of medical devices for the eye, on Tuesday reported a fourth quarter net loss and warned that earnings for its fiscal 2001 would fall short due to slower market growth.

For fourth quarter 2000, the company reported a net loss of $1.2 million, or 7 cents a share, on revenues of $13.7 million, compared with net income of $277,000, or 2 cents share, on revenues of $15.8 million for last year`s fourth quarter.

The company cited adverse exchange rates and higher marketing costs for the fourth quarter results. Also during the fourth quarter, the company took a charge of $1.5 million to establish a reserve against a receivable note to previous president and chairman John R. Wolf.

For fiscal 2001, the company said it expects to report break-even results on approximately $55 million in sales, compared with the First Call estimate of a 42-cent-per-share profit. The forecast was attributed to eroding market growth for certain products and a slower roll-out for a device used to treat glaucoma patients.

@ all

Was ist los bei Staar??? Wieso ist der Wert so abgestürzt?? Fischer hat die Aktien vorigen Monat ins sein Musterdepot nachgekauft, hat er sich da gewaltig geirrt? Hab ich irendwas verpasst?


Gruß Predo

Die Experten des Börsenmagazins "Der Aktionär" empfehlen risikoorientierten Anlegern das aktuelle Kursniveau von STAAR Surgical zum Einstieg und zum Aufbau langfristiger Positionen zu nutzen.

Das US-Unternehmen biete Lösungen für die Behandlung der häufigsten zeitgenössischen Augenerkrankungen. Es habe sich auf die Entwicklung, Produktion und Vermarktung medizinischer Geräte auf dem Gebiet der Augenheilkunde spezialisiert. Die Besonderheit der STAAR-Produkte liege darin, dass sie für einen minimaleninvasiven Eingriff konzipiert seien.

Die Experten erwarten nach 59 Mio. US-Dollar im Jahr 1999 für das jüngst zu Ende gegangene Geschäftsjahr 2000 eine Umsatzsteigerung auf mindestens 88,2 Mio. US-Dollar. Der Gewinn je Aktie werde voraussichtlich bei 6 Cents liegen. Für das laufende Geschäftsjahr 2001 prognostiziert "Der Aktionär" ein weiteres deutliches Umsatzwachstum auf knapp 105 Mio. US-Dollar. Der Gewinn je Aktie solle dann im Bereich von 42 Cents liegen.

Im Segment der Hersteller medizinischer Geräte zur Behandlung von Augenkrankheiten sei STAAR Surgical hervorragend positioniert. Bei einer derzeitigen Marktkapitalisierung von knapp 190 Mio. US-Dollar sei das Unternehmen jetzt noch äußerst günstig bewertet. Die Aktie eigne sich als spekulative Depotbeimischung für risikoorientierte Anleger.

Analyst: Der Aktionär
WKN der Aktie: 870353
KGV 01e: k.A.
Besprechungskurs: 11,43 US-Dollar
Kursziel: 18 US-Dollar
Rating des Analysten: spekulative Depotbeimischung

Quelle: Aktienresearch 18.01.2001 12:56

Hallo schwabday,

bei www.yahoo.com wirst du charts zu STAA finden.

Nähere Infos auch unter www.staar.com

Kursziel liegt bei 35 US$ auf 12-24 Monate.

winetrader